[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[3] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[4] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[5] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[6] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
[7] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[8] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[9] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[10] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[11] |
LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng.
Quality analysis of Guci tablets based on national drug evaluation sampling
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
|
[12] |
ZI Wenrui, YANG Qiuyue, SU Jun, XIE Jiang'an.
The research development of inoculation safety associated with licensed HPV vaccines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 311-316.
|
[13] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[14] |
WU Yanyan, HU Xuelian, DAN Chonghui.
Analysis of one case of double knee joint pain induced by linezolid tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 221-224.
|
[15] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|